TRCT
IDYA icon

Tower Research Capital (TRC)’s IDEAYA Biosciences IDYA Stock Holding History

Tower Research Capital (TRC)’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93K Sell
2,496
-6,580
-72% -$201K ﹤0.01% 2240
2026
Q1 		$302K Buy
9,076
+7,275
+404% +$244K 0.01% 1293
2025
Q4 		$62.3K Sell
1,801
-2,114
-54% -$67.4K ﹤0.01% 2267
2025
Q3 		$107K Sell
3,915
-5,623
-59% -$136K ﹤0.01% 1939
2025
Q2 		$200K Buy
9,538
+8,311
+677% +$159K 0.01% 1777
2025
Q1 		$20.1K Sell
1,227
-18,015
-94% -$384K ﹤0.01% 2961
2024
Q4 		$495K Buy
19,242
+14,852
+338% +$420K 0.01% 1070
2024
Q3 		$139K Sell
4,390
-10,563
-71% -$401K ﹤0.01% 1960
2024
Q2 		$525K Buy
14,953
+14,476
+3,035% +$573K 0.01% 1293
2024
Q1 		$20.9K Sell
477
-3,960
-89% -$170K ﹤0.01% 2959
2023
Q4 		$158K Buy
4,437
+3,132
+240% +$93.5K ﹤0.01% 2281
2023
Q3 		$35.2K Sell
1,305
-74
-5% -$1.88K ﹤0.01% 2876
2023
Q2 		$32.4K Sell
1,379
-6,964
-83% -$143K ﹤0.01% 2955
2023
Q1 		$115K Buy
8,343
+5,455
+189% +$90.9K ﹤0.01% 1737
2022
Q4 		$52K Buy
2,888
+827
+40% +$13.9K ﹤0.01% 2316
2022
Q3 		$31K Sell
2,061
-1,469
-42% -$19.1K ﹤0.01% 3578
2022
Q2 		$49K Buy
3,530
+3,007
+575% +$33.4K ﹤0.01% 2894
2022
Q1 		$6K Sell
523
-14,206
-96% -$209K ﹤0.01% 4888
2021
Q4 		$348K Buy
14,729
+11,257
+324% +$261K 0.01% 1372
2021
Q3 		$88K Buy
3,472
+676
+24% +$15.8K ﹤0.01% 2507
2021
Q2 		$59K Sell
2,796
-628
-18% -$12.9K ﹤0.01% 2888
2021
Q1 		$80K Sell
3,424
-407
-11% -$7.86K ﹤0.01% 2757
2020
Q4 		$54K Sell
3,831
-7,764
-67% -$105K ﹤0.01% 3047
2020
Q3 		$146K Buy
11,595
+10,994
+1,829% +$136K ﹤0.01% 2840
2020
Q2 		$9K Buy
+601
New +$4.74K ﹤0.01% 4053
2020
Q1 		– Sell
-436
Closed -$3K – 3433
2019
Q4 		$3K Sell
436
-1,265
-74% -$9.02K ﹤0.01% 2920
2019
Q3 		$15K Sell
1,701
-285
-14% -$2.17K ﹤0.01% 2665
2019
Q2 		$20K Buy
+1,986
New +$21.6K ﹤0.01% 2181

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Tower Research Capital (TRC)'s IDYA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its IDEAYA Biosciences (IDYA) stake by 72% in Q2 2026, selling an estimated $201K and leaving 2,496 shares worth $93K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Tower Research Capital (TRC) first reported a position in IDYA in Q2 2019 and has held it in 28 quarters since. The position peaked at $525K in Q2 2024. 285 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Tower Research Capital (TRC) held 2,496 shares of IDEAYA Biosciences worth $93K as of Q2 2026.
  • Tower Research Capital (TRC) sold 6,580 IDEAYA Biosciences shares in Q2 2026, an estimated $201K.
  • IDEAYA Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2240 holding.
  • Tower Research Capital (TRC) first reported a position in IDEAYA Biosciences in Q2 2019 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s IDEAYA Biosciences position peaked at $525K in Q2 2024.
  • 285 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.